Arbutus Biopharma (ABUS)
(Real Time Quote from BATS)
$4.14 USD
0.00 (0.00%)
Updated Sep 20, 2024 12:48 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
ABUS 4.14 0.00(0.00%)
Will ABUS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABUS
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) Moves 7.8% Higher: Will This Strength Last?
Other News for ABUS
Commit To Purchase Arbutus Biopharma At $3.50, Earn 12.9% Using Options
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical Developments
Arbutus Biopharma price target raised by $2 at Jefferies, here's why